Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
出版年份 2018 全文链接
标题
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
作者
关键词
Non-V600 BRAF mutation, Sorafenib, AZ628, Selumetinib, Apoptosis, Proliferation, Migration, MEK, RAF, Inhibition
出版物
BMC CANCER
Volume 18, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-05-08
DOI
10.1186/s12885-018-4455-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
- (2017) Jeremy C. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems
- (2017) Teddy S. Nagaria et al. Oncotarget
- Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK
- (2017) Luca Hegedüs et al. Frontiers in Oncology
- A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
- (2016) W. M. Tai et al. ANNALS OF ONCOLOGY
- Clinicopathological features and clinical outcomes associated withTP53andBRAFNon-V600mutations in cutaneous melanoma patients
- (2016) Dae Won Kim et al. CANCER
- Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
- (2016) Claire Tissot et al. LUNG CANCER
- Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm
- (2016) M. L. Turski et al. MOLECULAR CANCER THERAPEUTICS
- Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
- (2016) Raphaela Fritsche-Guenther et al. Oncotarget
- Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool
- (2015) Jamal Carter et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation
- (2015) María Sereno et al. ANTI-CANCER DRUGS
- Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
- (2015) Gang Zheng et al. BMC CANCER
- Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond
- (2015) Gennaro Gadaleta-Caldarola et al. Future Oncology
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
- (2015) Oliver Gautschi et al. Journal of Thoracic Oncology
- Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
- (2015) Mohammad Atefi et al. Molecular Cancer
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
- (2015) Tamás Garay et al. PLoS One
- Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
- (2015) Monika Joshi et al. PLoS One
- Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
- (2014) Anya M. Litvak et al. Journal of Thoracic Oncology
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma
- (2014) Vito W. Rebecca et al. Pigment Cell & Melanoma Research
- RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
- (2014) Simona Lamba et al. Cell Reports
- RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
- (2013) Matthew Holderfield et al. CANCER CELL
- Cell migration or cytokinesis and proliferation? – Revisiting the “go or grow” hypothesis in cancer cells in vitro
- (2013) Tamás Garay et al. EXPERIMENTAL CELL RESEARCH
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells
- (2012) Hiu‑Fung Yuen et al. BIOSCIENCE REPORTS
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
- (2012) Libero Santarpia et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma
- (2012) JOHN SHYI PENG YUEN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A New Mouse Model for the Study of Human Breast Cancer Metastasis
- (2012) Elizabeth Iorns et al. PLoS One
- The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor
- (2012) Jae-Kyung Won et al. Journal of Molecular Cell Biology
- Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro
- (2011) Yoon Woo Koh et al. ENDOCRINE-RELATED CANCER
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
- (2010) Tri K. Nguyen et al. LEUKEMIA RESEARCH
- Drug discovery: Inhibitors that activate
- (2010) Karen Cichowski et al. NATURE
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
- (2009) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
- (2008) W. M. Lin et al. CANCER RESEARCH
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
- (2008) K S M Smalley et al. ONCOGENE
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search